ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1631

Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells

Ken Yasaka1, Tomohide Yamazaki2, Hiroko Sato1, Tsuyoshi Shirai1, Hiroshi Fujii1, Tomonori Ishii3 and Hideo Harigae4, 1Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, 2SBI Biotech, Tokyo, Japan, 3Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, 4Department of Hematology, Tohoku University Hospital, Sendai, Japan

Meeting: ACR Convergence 2022

Keywords: B-Cell Targets, B-Lymphocyte, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

Session Type: Abstract Session

Session Time: 9:00AM-10:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies. In particular, targeting autoreactive B cells could be a promising therapy with minimal adverse effects and dependence on corticosteroids. Some phenotypically distinct B cell populations including IgD-, CD27-, CD11c+, and CXCR5lo double negative 2 (DN2) B cells, are expanded in lupus peripheral blood. DN2 B cells, which includes autoreactive B cells capable of differentiating into antibody secreting cells (ASCs), exhibit high intracellular expression of T-bet. Aiming to identify therapeutic targets in SLE, we found that phospholipase D4 (PLD4) is expressed on the surface of most plasmacytoid dendritic cells (pDCs) and less on the surface of B cells in healthy donors (HDs). PLD4 is believed to be an endolysosomal nuclease that regulates signals of toll-like receptors(TLRs) 7,8, and 9. We aimed to investigate the surface expression of PLD4 on B cells in SLE and to test PLD4+ B cells as a possible target for SLE treatment.

Methods: We developed monoclonal antibodies against PLD4. Flow cytometry was used to analyze PLD4 expression on several populations among peripheral blood mononuclear cells (PBMCs) from individuals with SLE (n = 40) and HDs (n = 11) classified by CD19, CD3, CD14, CD16, CD303, IgD, CD27, CD38, CD43, CD11c, and CXCR5. All SLE patients met ACR 1997 classification criteria. The prevalence of PLD4+ CD19+ B cells was compared between individuals with SLE and HDs, and their correlation with disease status was assessed. Furthermore, we investigated the intracellular expression of T-bet in SLE PLD4+ B cells. Certain compartments of B cells were isolated for culture to test their abilities to differentiate into ASCs by ELISpot.

Results: Among PBMCs, PLD4 was expressed only on pDCs and B cells. The ratio of PLD4+ CD19+ B cells to the whole CD19+ B cells was significantly higher in individuals with SLE than in HDs (mean ± SEM%, 11 ± 1.2% in SLE vs 2.1 ± 0.37% in HD, P < 1.0×10-6). In terms of cell size represented on forward scatter area density plot (FSC-A,) a subset of PLD4+ B cells was comparable to CD38+ CD43+ plasmablasts. We considered PLD4+ large B cells as distinct blastic B cell populations and named them “PLD4+ blasts.” Up to 90% of PLD4+ blasts were CD11c+ and CXCR5lo DN2, but few were plasmablasts. The frequencies of PLD4+ blasts significantly correlated with those of DN2 (spearman = +0.79, P < 1.0 × 105). When divided into four compartments by PLD4 and FSC-A (PLD4+/- and blast/small), PLD4+ blasts were exclusively and highly positive for intracellular T-bet expression ( >75% in PLD4+ blast, < 50% in the other compartments, n = 2). In some cases of new-onset SLE, PLD4+ blasts significantly decreased after immunosuppressive therapy (5.0% vs 2.0%, P < 1.0×104, paired t-test). Finally, when sorted and cultured in vitro with TLR 7 or 9 ligands, PLD4+ blasts differentiated into ASCs secreting comparable or higher levels of IgG than whole CD19+ B cells.

Conclusion: PLD4+ B cells are expanded in SLE and those blastic highly overlap with DN2. Targeting cell surface PLD4 could be a novel therapeutic strategy for SLE.

Supporting image 1

The prevalence of PLD4+ B cells in CD19+ B cells was compared between individuals with
SLE and healthy donors. SLE showed significant expansion of PLD4+ blasts.

Supporting image 2

Representative figures of flowcytometry on SLE B cells.
A) “PLD4+ blasts” expanded in SLE are as large as plasmablasts, but include few plasmablasts.
B) PLD4+ blasts are mostly composed of DN2 B cells. C) The frequencies of DN2 and PLD4+blasts are significantly correlated.

Supporting image 3

The prevalence of PLD4+ blasts was measured before and after immunosuppressive treatment in 11 new-onset SLE Patients. PLD4+ blasts significantly decreased by treatment.


Disclosures: K. Yasaka, None; T. Yamazaki, SBI Biotech Co., Ltd.; H. Sato, None; T. Shirai, None; H. Fujii, None; T. Ishii, None; H. Harigae, None.

To cite this abstract in AMA style:

Yasaka K, Yamazaki T, Sato H, Shirai T, Fujii H, Ishii T, Harigae H. Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/phospholipase-d-4-is-a-novel-surface-marker-of-a-distinctive-b-cell-population-overlapping-with-double-negative-2-b-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phospholipase-d-4-is-a-novel-surface-marker-of-a-distinctive-b-cell-population-overlapping-with-double-negative-2-b-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology